Home/Pipeline/AV-MEL-1

AV-MEL-1

Melanoma

Phase 1BActive

Key Facts

Indication

Melanoma

Phase

Phase 1B

Status

Active

Company

AIVITA Biomedical

About AIVITA Biomedical

AIVITA Biomedical is a private, clinical-stage biotech leveraging its proprietary stem cell and autologous immunotherapy platform to develop personalized vaccines. Its lead oncology programs target glioblastoma and melanoma, with a Phase 2/3 trial planned for glioblastoma and a Phase 1B trial ongoing in melanoma. The company has also developed a multi-pathogen vaccine kit and funds its R&D in part through a clinically validated skincare product line.

View full company profile

Therapeutic Areas

Oncology Infectious Disease

Other Melanoma Drugs

Drug	Company	Phase	Status
ABD-3001	Advanced Biodesign	Phase 1	Active
SUPLEXA	Alloplex Biotherapeutics	Phase 1	Completed
Cannabics® MLN-33	CNBX Pharmaceuticals	Discovery	Outline for POC study in mice
Melanoma Immunotherapy	Vaccizone	Pre-clinical	Active
Undisclosed RNA Immunotherapy	Epitopea	Pre-clinical	Active
Melanoma Monitoring Solution	Oncobit	Commercial	Active
Undisclosed Enhanced Antibody Program	Score Pharma	Pre-clinical	Active
ASO for Melanoma	Carnation Therapeutics	Pre-clinical	Active
Personalized DNA Cancer Vaccine	Neomatrix	Pre-clinical	Active